Vanguard Personalized Indexing Management
LXRX icon

Vanguard Personalized Indexing Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
54,334
-631
-1% -$1.23K ﹤0.01% 2004
2026
Q1 		$85.7K Sell
54,965
-11,602
-17% -$16.9K ﹤0.01% 1970
2025
Q4 		$76.6K Hold
66,567
– – ﹤0.01% 1840
2025
Q3 		$89.9K Buy
66,567
+1,237
+2% +$1.4K ﹤0.01% 1837
2025
Q2 		$61.8K Buy
65,330
+28,594
+78% +$18.5K ﹤0.01% 1800
2025
Q1 		$16.9K Buy
36,736
+13,513
+58% +$8.53K ﹤0.01% 1791
2024
Q4 		$17.1K Buy
23,223
+3,301
+17% +$3.98K ﹤0.01% 1777
2024
Q3 		$31.3K Buy
19,922
+593
+3% +$1.06K ﹤0.01% 1717
2024
Q2 		$32.5K Buy
19,329
+3,844
+25% +$6.89K ﹤0.01% 1619
2024
Q1 		$37.2K Buy
15,485
+312
+2% +$670 ﹤0.01% 1579
2023
Q4 		$23.2K Buy
+15,173
New +$18K ﹤0.01% 1541

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Personalized Indexing Management's LXRX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 1.1% in Q2 2026, selling an estimated $1.23K and leaving 54,334 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Vanguard Personalized Indexing Management first reported a position in LXRX in Q4 2023 and has held it in 11 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 54,334 shares of Lexicon Pharmaceuticals worth $130K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 631 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $1.23K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2004 holding.
  • Vanguard Personalized Indexing Management first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.